184 related articles for article (PubMed ID: 26361970)
1. Maintenance therapy for metastatic colorectal cancer.
Giampieri R; Cascinu S
Lancet Oncol; 2015 Oct; 16(13):1281-2. PubMed ID: 26361970
[No Abstract] [Full Text] [Related]
2. Maintenance treatment in metastatic colorectal cancer.
Chibaudel B; Bonnetain F; Tournigand C; de Gramont A
Lancet Oncol; 2015 Dec; 16(16):e583-4. PubMed ID: 26678202
[No Abstract] [Full Text] [Related]
3. Maintenance treatment in metastatic colorectal cancer.
Simkens LH; van Tinteren H; Punt CJ; Koopman M
Lancet Oncol; 2015 Dec; 16(16):e582-3. PubMed ID: 26678201
[No Abstract] [Full Text] [Related]
4. Maintenance treatment in metastatic colorectal cancer - Authors' reply.
Hegewisch-Becker S; Graeven U; Arnold D
Lancet Oncol; 2015 Dec; 16(16):e584-5. PubMed ID: 26678203
[No Abstract] [Full Text] [Related]
5. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
6. FOLFOXIRI and bevacizumab in metastatic colorectal cancer.
Rahman A
Lancet Oncol; 2014 Dec; 15(13):e590. PubMed ID: 25499288
[No Abstract] [Full Text] [Related]
7. Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?
Semira C; Wong HL; Field K; Lee M; Lee B; Nott L; Shapiro J; Wong R; Tie J; Tran B; Richardson G; Zimet A; Lipton L; Tamjid B; Burge M; Ma B; Johns J; Harold M; Gibbs P
Intern Med J; 2019 Apr; 49(4):446-454. PubMed ID: 30230679
[TBL] [Abstract][Full Text] [Related]
8. Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2-Related Mechanism.
Kim S; Cayre A; Jary M; Jacquin M; Arbez-Gindre F; Fein F; Lakkis Z; Nguyen T; Borg C
Clin Colorectal Cancer; 2016 Dec; 15(4):e229-e234. PubMed ID: 27600470
[No Abstract] [Full Text] [Related]
9. A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study.
Nakayama N; Sato A; Tanaka S; Shimada K; Konishi K; Sasaki E; Hibi K; Ichikawa H; Kikuchi Y; Sakuyama T; Sekikawa T; Hayashi K; Nishina H;
Invest New Drugs; 2015 Aug; 33(4):954-62. PubMed ID: 25937430
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
[TBL] [Abstract][Full Text] [Related]
11. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.
Azzariti A; Porcelli L; Brunetti O; Del Re M; Longo V; Nardulli P; Signorile M; Xu JM; Calabrese A; Quatrale AE; Maiello E; Lorusso V; Silvestris N
World J Gastroenterol; 2016 Jul; 22(27):6287-95. PubMed ID: 27468218
[TBL] [Abstract][Full Text] [Related]
12. FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).
Aparicio T; Linot B; Le Malicot K; Bouché O; Boige V; François E; Ghiringhelli F; Legoux JL; Ben Abdelghani M; Phelip JM; Faroux R; Dahan L; Taieb J; Bedenne L
Dig Liver Dis; 2015 Apr; 47(4):271-2. PubMed ID: 25677925
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Rivera F; Valladares M; Gea S; López-Martínez N
J Med Econ; 2017 Jun; 20(6):574-584. PubMed ID: 28107090
[TBL] [Abstract][Full Text] [Related]
14. Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer.
Umehara M; Umehara Y; Takahashi K; Murata A; Nishikawa S; Tokura T; Matsuzaka M; Tanaka R; Morita T
Anticancer Res; 2016 Apr; 36(4):1949-54. PubMed ID: 27069185
[TBL] [Abstract][Full Text] [Related]
15. Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer.
Miyamoto Y; Oki E; Emi Y; Tokunaga S; Shimokawa M; Ogata Y; Akagi Y; Sakamoto Y; Tanaka T; Saeki H; Maehara Y; Baba H
Anticancer Res; 2018 Jan; 38(1):491-499. PubMed ID: 29277814
[TBL] [Abstract][Full Text] [Related]
16. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
Nagasaka T; Mishima H; Sawaki A; Shimokawa M; Inukai M; Shinozaki K; Tanioka H; Nasu J; Nishina T; Hazama S; Okajima M; Yamaguchi Y
BMJ Open; 2016 Jun; 6(6):e011454. PubMed ID: 27256093
[TBL] [Abstract][Full Text] [Related]
17. When a good call leads to a bad connection: colovesical fistula in colorectal cancer treated with bevacizumab.
Chen J; Smalligan RD; Nadesan S
Hosp Pract (1995); 2016 Aug; 44(3):120-2. PubMed ID: 27309405
[TBL] [Abstract][Full Text] [Related]
18. BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.
Benson AB; Kiss I; Bridgewater J; Eskens FA; Sasse C; Vossen S; Chen J; Van Sant C; Ball HA; Keating A; Krivoshik A
Clin Cancer Res; 2016 Oct; 22(20):5058-5067. PubMed ID: 27401244
[TBL] [Abstract][Full Text] [Related]
19. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
20. Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer.
Díaz-Rubio E; Pietrantonio F; de Braud F
Oncologist; 2012; 17(11):1426-8. PubMed ID: 23073991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
